Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Scilex Holding Company (SCLX)

7.82   0.45 (6.11%) 03-24 16:00
Open: 7.28 Pre. Close: 7.37
High: 7.83 Low: 7.05
Volume: 141,450 Market Cap: 1,140(M)

Technical analysis

as of: 2023-03-24 4:29:39 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 9.65     One year: 11.15
Support: Support1: 6.19    Support2: 5.15
Resistance: Resistance1: 8.27    Resistance2: 9.55
Pivot: 7.87
Moving Average: MA(5): 7.8     MA(20): 8.11
MA(100): 7.02     MA(250): 8.97
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 42.6     %D(3): 47
RSI: RSI(14): 49
52-week: High: 11.68  Low: 2.86
Average Vol(K): 3-Month: 382 (K)  10-Days: 191 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ SCLX ] has closed above bottom band by 47.3%. Bollinger Bands are 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.83 - 7.87 7.87 - 7.91
Low: 6.97 - 7 7 - 7.04
Close: 7.76 - 7.82 7.82 - 7.88

Company Description

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

Headline News

Tue, 21 Mar 2023
Scilex Holding Company Announces Financing of up to $25 Million ... - GlobeNewswire

Thu, 16 Mar 2023
SORRENTO THERAPEUTICS, INC. Management's Discussion and ... -

Thu, 09 Mar 2023
Scilex Holding Full Year 2022 Earnings: US$0.17 loss per share (vs US$0.45 loss in FY 2021) - Simply Wall St

Wed, 08 Mar 2023
Scilex Holding Company and CH Trading Group Announce Territory Distribution Agreement to Expand Commercialization of ZTlido® for the Middle East and North Africa (MENA) With $105 Million Minimum Multi-Year Purchase Commitment - Yahoo Finance

Thu, 02 Mar 2023
Scilex Holding (NASDAQ:SCLX) adds US$65m to market cap in the past 7 days, though investors from a year ago are still down 16% - Simply Wall St

Mon, 27 Feb 2023
Scilex Holding Company (SCLX) Announces Commercial Launch of ... -

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. 146 (M)
Shares Float 86 (M)
% Held by Insiders 43 (%)
% Held by Institutions 7.4 (%)
Shares Short 708 (K)
Shares Short P.Month 566 (K)

Stock Financials

EPS -0.18
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.25
Profit Margin (%) -61.5
Operating Margin (%) -133.2
Return on Assets (ttm) -38.5
Return on Equity (ttm) 0
Qtrly Rev. Growth 44.2
Gross Profit (p.s.) 0.18
Sales Per Share 0.26
EBITDA (p.s.) -0.33
Qtrly Earnings Growth 0
Operating Cash Flow -21 (M)
Levered Free Cash Flow -103 (M)

Stock Valuations

PE Ratio -46
PEG Ratio 0
Price to Book value 30.07
Price to Sales 29.98
Price to Cash Flow -53.64

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.